ACXP (39) SKYE (36) SCNX (42) XCUR (35) ⌘ Pro Terminal →

Alzamend Neuro Inc. (ALZN) — RQD Stock Rating Cockpit

$1.22 +2.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Alzamend Neuro Inc. (ALZN) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $5.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALZN)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

37.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE21% OF RANGE

L: $1$1.22H: $3

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ALZN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (48)

16/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like ALZN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALZN)

✓Walkthrough of ALZN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.02%📐 HORIZONTAL RANGE

2026-10-30O $1.29H $1.33L $1.21C $1.22VOL 25.0K

RES: $2.16SUP: $1.06SMA50: $1.53SMA200: $1.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALZN Butterfly Map → + Track ALZN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALZN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALZN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALZN)

Health Care Rank #429 of 1016 ⚔️ ACXP vs ALZN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALZN vs. ACXP, SKYE, SCNX, XCUR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alzamend Neuro Inc. (ALZN) ranks #429 by composite RQD confidence (47/100, grade D) and #930 by equity capitalization ($5.9M). Within this direct 5-issuer industry benchmark cohort, ALZN leads on earnings valuation at N/A trailing P/E, while ALZN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ALZN currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALZN ACTIVE Alzamend Neuro Inc.	D	47/100	—	—	-35.0%	+2.52%	$5.9M	Benchmark Subject
ACXP Acurx Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.9M	/acxp-vs-alzn →
SKYE Skye Bioscience Inc.	D-	36/100	—	—	-35.0%	-13.82%	$5.8M	/skye-vs-alzn →
SCNX Scienture Holdings Inc.	D-	42/100	—	76.8%	-35.0%	+2.65%	$5.7M	/scnx-vs-alzn →
XCUR Exicure Inc.	D-	35/100	—	—	-35.0%	-8.04%	$6.1M	/xcur-vs-alzn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001677077

In its most recent audited fiscal period (FY2025, filed 2026-04-30), Alzamend Neuro Inc. (ALZN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.8M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-22.8% YoY). On the balance sheet, ALZN closed FY2025 with $4.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-04-30	$0	-$8.8M	-$8.1M	-$8.1M	$4.0M	—
FY2024 (FY)	2025-04-30	$0	-$4.5M	-$6.6M	-$6.6M	$4.2M	—
FY2023 (FY)	2024-04-30	$0	-$9.9M	-$8.3M	-$8.3M	—	—

3. ALZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Alzamend Neuro Inc. (NASDAQ: ALZN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.22 (+2.52% 1D, market cap $5.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALZN ranks #429 in composite RQD confidence.

How does ALZN compare to ACXP and SKYE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALZN carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M) and SKYE (Skye Bioscience Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, ALZN leads on earnings multiple (N/A) while ALZN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALZN?

Per ALZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001677077), Alzamend Neuro Inc. generated $0 in revenue, -$8.8M in net income, and -$8.1M in free cash flow against $4.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALZN trading relative to its 50-day, 200-day, and 52-week technical levels?

ALZN last traded at $1.22 (+2.52% on volume of 15,793 shares), positioning the stock -20.26% below its 50-day simple moving average ($1.53) and -17.57% below its 200-day simple moving average ($1.48). Across its 52-week range of $0.84 to $2.61, ALZN sits at the 21.5% percentile with a 14-day RSI of 37.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.07 to $1.37).

ALZN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ALZN stock right now?

Alzamend Neuro Inc. (ALZN) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is ALZN's 12-month price target and RQD AI Jury consensus?

ALZN's 12-month base price target is $1.16 (range $0.9 to $2.74), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ALZN RQD Cockpit ALZN 12M Forecast ALZN Earnings & Move ALZN Dividends & DRIP ALZN Insiders & 13F ALZN Whale Options ALZN Profit Sankey ALZN News & Why